ASIT AIW ASIT biotech: Publication Related to a Transparency Notification

Transparency directive : regulatory news

12/02/2018 19:30

16/01/2019 07:00
19/12/2018 07:00
17/12/2018 07:00
06/12/2018 18:05
28/11/2018 18:00
26/11/2018 07:00
19/11/2018 07:00
16/11/2018 08:00
12/11/2018 18:00
05/11/2018 14:00

(article 14, subparagraph 1 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies)

Regulatory News:

ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 9 February, 2018, the result of which is - following a capital increase completed on 25 January 2019 - that SA SFPI now has 8.87% of the Company’s voting rights, and has thus decreased its stake below the 10% threshold.

The statement dated 9 February 2018 notably includes the following information:

  • Purpose of the notification

Passive crossing of a threshold

  • Notification by

A parent undertaking or a controlling person

  • Person subject to the notification requirement

SFPI SA – Avenue Louise 32 b4, 1050 Brussels, Belgium

Etat Belge – Rue de la Loi 12, 1000 Brussels, Belgium

  • Date of the transaction

25 January 2018

  • Threshold crossed (%)

Downward crossing of the 10% threshold.

  • Denominator

A total of 15,262,544 voting rights

  • This notification is available on ASIT biotech’s website, in the Documentation / Regulated information section:


About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at

Thierry Legon, CEO
ASIT biotech
Tel.: +32 2 264 03 90
Media and Investor Relations - France
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
Media Relations - Belgium
Laure-Eve Monfort
Tel.: +32 2 290 90 93